| Trial ID: | L5627 |
| Source ID: | NCT01507285
|
| Associated Drug: |
Liraglutide
|
| Title: |
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2|Healthy
|
| Interventions: |
DRUG: liraglutide|DRUG: placebo
|
| Outcome Measures: |
Primary: Area under the Curve | Secondary: Cmax, maximum concentration|tmax, time to maximum concentration|t½, terminal half-life|Adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
1999-08
|
| Completion Date: |
1999-11
|
| Results First Posted: |
|
| Last Update Posted: |
2023-11-02
|
| Locations: |
Novo Nordisk Investigational Site, Manchester, M15 6SH, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01507285
|
